The Prevention of Hereditary Breast and Ovarian Cancer: A Personal View

Hereditary Cancer in Clinical Practice

Steven Narod¹ 

[1] Centre for Research on Women's Health, University of Toronto, Toronto, Ontario, Canada

关键词: chemoprevention;    ovarian cancer;    breast cancer;    BRCA2;    BRCA1;   

Others  :  825569
DOI  :  10.1186/1897-4287-2-1-5

 received in 2004-02-09, accepted in 2004-02-20,  发布年份 2004

【 摘 要 】

Options for the prevention of hereditary breast and ovarian cancer include screening, preventive surgery and chemoprevention. Screening studies with magnetic resonance imaging of the breast are promising but the technology is not widespread and MRI is unlikely to be available as a screening tool in the near future. Prophylactic oophorectomy and mastectomy are effective preventive measures and are gaining in acceptance by patients and physicians. Preventive mastectomy is effective against both primary and contralateral breast cancer. Oophorectomy prevents ovarian cancer, and if done prior to menopause, will prevent breast cancer as well. Tamoxifen has been shown to prevent contralateral breast cancers in BRCA1 and BRCA2 carriers but is not widely accepted as a means of primary prevention. Oral contraceptives and tubal ligation will reduce the risk of hereditary ovarian cancer and should be considered in women who wish to retain ovarian function.

   

【 参考文献 】

• [1]Lerman C, Narod S, Schulman K, Hughes C, Main D, Bonney G, Lynch J, Gomez-Caminero A, Fulmore C, Snyder C, Lemon S, Lynch H: Predictors of utilization of BRCA1 testing in hereditary breast-ovarian cancer families: implications for patient education and informed consent. JAMA 1996, 275:1885-1892.
• [2]Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans S, Seynaeve C, Menke-Pluymres MB, Bartels CC, Verhoog LC, Ouweland AM, Niermeijer MF, Brekelmans CT, Klijn JG: Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. New Engl J Med 2001, 345:159-164.
• [3]Hartmann LC, Sellers TA, Schaid DJ, Franks TS, Soderberg CL, Sitt DL, Frost MH, Grant CS, Donohue JH, Woods JE, McDonnell SK, Vockley CW, Deffenbagh A, Couch FJ, Jenkins RB: Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene carriers. J Natl Cancer Inst 2001, 7:1633-7.
• [4]Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivitto I, Warner E, Olopade OI, Eisen A, Weber B, McLellan J, Sun P, Foulkes WD, Narod SA: Contralateral breast cancer in BRCA1 and BRCA2 carriers. J Clin Oncol, in press.
• [5]Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, Linder-Stephenson L, Salerno G, Conway TA, Lynch HT: Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996, 77:697-709.
• [6]Foulkes WD, Wong N, Brunet J-S, Narod SA, Begin LR, Zhang JC, Martinez JJ, Tonin PN, Karp SE, Pollak MN: Germline BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clinical Cancer Research 1997, 6:2465-2469.
• [7]Foulkes WD, Chappuis PO, Wong N, Brunet J-S, Vesprini D, Rozen F, Yuan ZQ, Kuperstein G, Narod SA, Bégin LR: Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol 2000, 11:307-313.
• [8]Foulkes WD, Metcalfe K, Hanna W, Lynch HT, Ghadirian P, Tung N, Olopade O, Weber B, McLennan J, Olivotto IA, Sun P, Chappuis PO, Begin LR, Brunet J-S, Narod SA: Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer 2003, 98:1569-1577.
• [9]Warner E, Plewes D, Shumak R, Di Prospero L, Yaffe M, Goel V, Ramsay E, Chart P, Cole D, Catzavelos C, Taylor G, Narod SA: Comparison of breast magnetic resonance imaging, mammography and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 2001, 19:3524-3531.
• [10]Kuhl CK, Schmutzler RK, Leutner CC, Kempe A, Wardelmann E, Hocke A, Maringa M, Pfeifer U, Krebs D, Schild HH: Breast MRI imaging screening in 192 women proved or suspected to be carriers of breast cancer susceptibility gene: preliminary results. Radiology 2000, 215:267-279.
• [11]Van Leeuwen FE, Klokman WJ, Stovall M, Dahler EC, van't Veer M, Noordijk EM, Crommelin MA, Aleman BM, Broeks A, Gospodarowicz M, Travis LB, Russell NS: Roles of radiation dose, chemotherapy and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003, 95:971-980.
• [12]Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Lynch HT, Garber JE, Godwin AK, Daly MB, Narod SA, Neuhausen SL, Weber BL: Reduction in breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999, 91:1475-1479.
• [13]Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade O, Weber BL: Reduction in cancer risk after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. New Engl J Med 2002, 346:1616-1622.
• [14]Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. New Eng J Med 2002, 346:1660-1662.
• [15]Miller AB, To T, Baines CJ, Wall C: The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40-49 years. Ann Intern Med 2002, 137:305-312.
• [16]Tabar L, Duffy SW, Vitak B, Chen HH, Prevost TC: The natural history of breast carcinoma: what have we learned from screening? Cancer 1999, 86:449-462.
• [17]Goffin J, Chappuis PO, Wong N, Foulkes WD: Re: Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 2001, 93:1754-5.
• [18]Brekelmans CT, Seynaeve C, Bartels CC, Tilanus-Linthorst MM, Meijers-Heijboer EJ, Crepin CM, van Geel AA, Menke M, Verhoog LC, Ouweland A, Obdeijn IM, Klijn JG, Rotterdam Committee for Medical and Genetic Counseling: Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 2001, 15:924-30.
• [19]Narod SA: Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer 2002, 2:113-123.
• [20]King M-C, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford T, Dunn BK, Costantino J, Wickerham L, Wolmark N, Fisher B: Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Breast and Bowel (NSABP-P1) Breast Cancer Prevention Trial.
• [21]Narod SA, Brunet J-S, Ghadirian P, Robson M, Heimdahl K, Neuhausen S, Stoppa Lyonnet D, Lerman C, Radice P, de los Rios P, Weber B, Lynch H, for the Hereditary Breast Cancer Clinical Study Group: Tamoxifen and the risk of contralateral breast cancer in BRCA1 and BRCA2 carriers. Lancet 2000, 356:1876-1881.
• [22]Peshkin BN, Isaacs C, Finch C, Kent S, Schwartz MD: Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians. J Clin Oncol 2003, 21:4322-4328.
• [23]Brandt PA, Zeegers MP, Bode P, Goldbohm RA: Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiol Biomarkers Prev 2003, 12:866-871.
• [24]Giovanucci E: Tomatoes, tomato-based products, lycopene and cancer: review of the epidemiologic literature. J Natl Cancer Inst 1999, 91:317-331.
• [25]Narod SA, Sun P, Ghadirian P, Lynch H, Isaacs C, Garber J, Weber B, Karlan B, Fishman D, Rosen B, Tung N, Neuhausen SL, the Hereditary Ovarian Cancer Clinical Study Group: Tubal ligation and the risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations. Lancet 2001, 357:1467-1470.
• [26]Narod SA, Risch H, Moslehi R, Neuhausen S, Moller P, Olsson H, Provencher D, Radice P, Evans G, Bishop S, Brunet J-S, Ponder B: Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 1998, 339:424-428.
• [27]Narod SA, Dubé M-P, Klijn J, Lubinski J, Lynch HT, Ghadirian P, Provencher D, Heimdal K, Moller P, Isaacs C, Weber B, Friedman E, Gershoni-Baruch R, Rennert G, Pasini B, Wagner T, Daly M, Garber JE, Neuhausen S, Robson M, Offit K, Ainsworth P, Olsson H, Evans G, Osborne M, Couch F, Foulkes W, Warners E, Kim-Sing C, Olopade O, Tung N, Saal HM, Weitzel J, Merajver S, Gauthier-Villars M, Jernstrom H, Sun P, Brunet J-S: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 carriers. J Natl Can Inst 2002, 94:1773-1779.
• [28]Liede A, Karlan BY, Baldwin RL, Platt LD, Kuperstein G, Narod SA: Ovarian cancer incidence in a screened population of Jewish women. J Clin Oncol 2002, 20:1570-7.